Diamyd´s subscription warrant provides SEK 28 million cash injection

Diamyd Medical reports today that the subscription of new shares upon exercise of the subscription warrant DIAM TO2B brought in SEK 28 million in cash injection.

– We appreciate the continued support from our shareholders and warrant owners. Diamyd has made good progress during the year and this together with a large international interest for the Company, has made it possible to exercise the subscription warrants at the exercise price, says Elisabeth Lindner, President and CEO of Diamyd Medical. In May 2008 Diamyd Medical issued a direct emission of shares, where each share was followed by a subscription warrant giving the right to subscribe one share in Diamyd Medical at the exercise price SEK 100 during the period March 16 to April 17, 2009. The subscription warrant Diamyd Medical TO 2B has now been exercised and has brought MSEK 28 in cash injection. The money will be used for clinical operations. The subscription warrants that were not exercised have expired without value.

Tags: